Interferon-β(1b) augments activation-induced T-cell death in multiple sclerosis patients

Lancet

Volumn 353, Issue 9162, 1999, Pages 1413-1414

  Kaser, Arthur ^a   Deisenhammer, Florian ^a   Berger, Thomas ^a   Tilg, Herbert ^a  

^a Department of Medicine   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0033599730     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00622-4     Document Type: Article

References (5)

1. Pender M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 351:1998;978-981.
2. Placebo-controlled multicentre randomised trial on interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:1998;1491-1497.
3. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 352:1998;1498-1504.
4. Kaser A., Nagata S., Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine. . in press.
5. Ju S.T., Panka D.J., Cui H.et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.